| Nathanael A Slater, DO | |
|
250 Pleasant St, Concord, NH 03301-2598 | |
| (603) 789-9103 | |
| (603) 227-7832 |
| Full Name | Nathanael A Slater |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 19 Years |
| Location | 250 Pleasant St, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043365877 | NPI | - | NPPES |
| 110092896A | Medicaid | MA | |
| 3099810 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 236315 (Massachusetts) | Secondary |
| 207L00000X | Anesthesiology | 16846 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Concord Hospital | Concord, NH | Hospital |
| Lakes Region General Hospital | Laconia, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Professional Association | 3375532435 | 55 |
| Concord Hospital Inc | 6103721790 | 462 |
News Archive
When remote regions with limited health facilities experience an epidemic, they need portable diagnostic equipment that functions outside the hospital. As demand for such equipment grows, EPFL researchers have developed a low-cost and portable microfluidic diagnostic device. It has been tested on Ebola and can be used to detect many other diseases.
First generation cephalosporins—antibiotics introduced as a treatment against bacterial infections in 1963—now show promise for tuberculosis (TB) therapy, according to new research published in Scientific Reports.
Does the environment encountered early in life have permanent and predictable long-term effects in adulthood? Such effects have been reported in numerous organisms, including humans.
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, commented today on Roche's corporate restructuring and its implications on RNAi therapeutics.
In this PLoS Medicine editorial, the editors review progress toward the journal's goal of reflecting and addressing inequity in the burden of ill-health around the world as part of the Global Burden of Disease project - a "comprehensive work studying the burden of ill-health and death resulting from specific conditions, injuries, and risk factors," a PLoS press release writes.
› Verified 9 days ago
| Entity Name | Concord Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194778571 PECOS PAC ID: 6103721790 Enrollment ID: O20040405000916 |
News Archive
When remote regions with limited health facilities experience an epidemic, they need portable diagnostic equipment that functions outside the hospital. As demand for such equipment grows, EPFL researchers have developed a low-cost and portable microfluidic diagnostic device. It has been tested on Ebola and can be used to detect many other diseases.
First generation cephalosporins—antibiotics introduced as a treatment against bacterial infections in 1963—now show promise for tuberculosis (TB) therapy, according to new research published in Scientific Reports.
Does the environment encountered early in life have permanent and predictable long-term effects in adulthood? Such effects have been reported in numerous organisms, including humans.
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, commented today on Roche's corporate restructuring and its implications on RNAi therapeutics.
In this PLoS Medicine editorial, the editors review progress toward the journal's goal of reflecting and addressing inequity in the burden of ill-health around the world as part of the Global Burden of Disease project - a "comprehensive work studying the burden of ill-health and death resulting from specific conditions, injuries, and risk factors," a PLoS press release writes.
› Verified 9 days ago
| Entity Name | Anesthesia Associates Professional Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881791150 PECOS PAC ID: 3375532435 Enrollment ID: O20040512000620 |
News Archive
When remote regions with limited health facilities experience an epidemic, they need portable diagnostic equipment that functions outside the hospital. As demand for such equipment grows, EPFL researchers have developed a low-cost and portable microfluidic diagnostic device. It has been tested on Ebola and can be used to detect many other diseases.
First generation cephalosporins—antibiotics introduced as a treatment against bacterial infections in 1963—now show promise for tuberculosis (TB) therapy, according to new research published in Scientific Reports.
Does the environment encountered early in life have permanent and predictable long-term effects in adulthood? Such effects have been reported in numerous organisms, including humans.
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, commented today on Roche's corporate restructuring and its implications on RNAi therapeutics.
In this PLoS Medicine editorial, the editors review progress toward the journal's goal of reflecting and addressing inequity in the burden of ill-health around the world as part of the Global Burden of Disease project - a "comprehensive work studying the burden of ill-health and death resulting from specific conditions, injuries, and risk factors," a PLoS press release writes.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nathanael A Slater, DO 250 Pleasant St, Concord, NH 03301-7559 Ph: (603) 789-9103 | Nathanael A Slater, DO 250 Pleasant St, Concord, NH 03301-2598 Ph: (603) 789-9103 |
News Archive
When remote regions with limited health facilities experience an epidemic, they need portable diagnostic equipment that functions outside the hospital. As demand for such equipment grows, EPFL researchers have developed a low-cost and portable microfluidic diagnostic device. It has been tested on Ebola and can be used to detect many other diseases.
First generation cephalosporins—antibiotics introduced as a treatment against bacterial infections in 1963—now show promise for tuberculosis (TB) therapy, according to new research published in Scientific Reports.
Does the environment encountered early in life have permanent and predictable long-term effects in adulthood? Such effects have been reported in numerous organisms, including humans.
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, commented today on Roche's corporate restructuring and its implications on RNAi therapeutics.
In this PLoS Medicine editorial, the editors review progress toward the journal's goal of reflecting and addressing inequity in the burden of ill-health around the world as part of the Global Burden of Disease project - a "comprehensive work studying the burden of ill-health and death resulting from specific conditions, injuries, and risk factors," a PLoS press release writes.
› Verified 9 days ago
Kathryn S Lemmon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 246 Pleasant St, Suite 105 B Eye Anesthesia Of Concord Pllc, Concord, NH 03301 Phone: 603-224-6503 | |
Dr. Victoria Kogan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Gregory F. Martin, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Roman Plachinta, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Pillsbury St, Ste 202, Concord, NH 03301 Phone: 603-224-4776 Fax: 603-228-2113 | |
Dr. John M Riddell, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St., Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Margaret A Pitts, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St., Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 |